Leap Therapeutics (LPTX) News Today $0.48 0.00 (-0.52%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.48 +0.00 (+0.17%) As of 02/21/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period What is HC Wainwright's Estimate for LPTX FY2029 Earnings?Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) - Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Leap Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per shaJanuary 30, 2025 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Downgraded to Hold Rating by Baird R WBaird R W cut shares of Leap Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday.January 30, 2025 | marketbeat.comLeap Therapeutics downgraded to Neutral from Buy at H.C. WainwrightJanuary 29, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Leap Therapeutics (LPTX)January 29, 2025 | msn.comLeap Therapeutics stock rating cut by H.C. Wainwright to NeutralJanuary 29, 2025 | msn.comLeap Therapeutics (NASDAQ:LPTX) Downgraded by HC Wainwright to NeutralHC Wainwright downgraded Leap Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday.January 29, 2025 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Stock Rating Lowered by Robert W. BairdRobert W. Baird lowered Leap Therapeutics from an "outperform" rating to a "neutral" rating and dropped their price target for the stock from $9.00 to $1.25 in a report on Wednesday.January 29, 2025 | marketbeat.comLeap Therapeutics Shares Slide After Initial Mid-Stage Cancer-Drug ResultsJanuary 28, 2025 | marketwatch.comLeap Therapeutics stock hits 52-week low at $0.8January 28, 2025 | msn.comLeap Therapeutics stock plummets as it will discontinue DisTinGuish study in advanced gastric cancerJanuary 28, 2025 | msn.comLeap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish StudyJanuary 28, 2025 | prnewswire.comPositive Buy Rating for Leap Therapeutics Driven by Promising Clinical Results and Robust Pipeline AdvancementsJanuary 17, 2025 | markets.businessinsider.comLeap Therapeutics (NASDAQ:LPTX) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $5.50 price target on shares of Leap Therapeutics in a research note on Thursday.January 16, 2025 | marketbeat.comLeap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon CancerJanuary 6, 2025 | seekingalpha.comLeap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | prnewswire.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Up 50.7% in DecemberLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 2,140,000 shares, an increase of 50.7% from the November 30th total of 1,420,000 shares. Based on an average trading volume of 352,300 shares, the days-to-cover ratio is currently 6.1 days. Approximately 7.5% of the shares of the company are sold short.December 28, 2024 | marketbeat.comLeap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | prnewswire.comBuy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial OutlookNovember 15, 2024 | markets.businessinsider.comLeap Therapeutics Reports Q3 2024 Progress and FinancialsNovember 15, 2024 | markets.businessinsider.comSimplify Asset Management Inc. Grows Position in Leap Therapeutics, Inc. (NASDAQ:LPTX)Simplify Asset Management Inc. raised its stake in Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 67.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,056,895 shares of the company's stock after buying anNovember 15, 2024 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $5.50 price target on shares of Leap Therapeutics in a research report on Friday.November 15, 2024 | marketbeat.comLeap Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | prnewswire.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Sees Significant Drop in Short InterestLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 723,500 shares, a decline of 19.5% from the September 30th total of 899,100 shares. Based on an average daily trading volume, of 149,100 shares, the short-interest ratio is presently 4.9 days. Approximately 2.4% of the shares of the stock are short sold.October 27, 2024 | marketbeat.comLeap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsSeptember 30, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Stock Crosses Below Fifty Day Moving Average of $2.58Leap Therapeutics (NASDAQ:LPTX) Shares Cross Below 50-Day Moving Average of $2.58September 28, 2024 | marketbeat.comSimplify Asset Management Inc. Buys 255,293 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)Simplify Asset Management Inc. increased its position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 67.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 631,269 shares of the compaSeptember 20, 2024 | marketbeat.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest UpdateLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 1,230,000 shares, a growth of 17.1% from the July 31st total of 1,050,000 shares. Approximately 4.1% of the company's shares are sold short. Based on an average trading volume of 134,000 shares, the short-interest ratio is presently 9.2 days.August 31, 2024 | marketbeat.comLeap Therapeutics Inc (5MC.MU)August 23, 2024 | sg.finance.yahoo.com3 Trending Biotech Penny StocksAugust 22, 2024 | 247wallst.comVanguard Group Inc. Acquires 457,904 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)Vanguard Group Inc. boosted its holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 111.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 867,708 shares of the company's stock after acquirAugust 20, 2024 | marketbeat.comLeap Therapeutics, Inc. (NASDAQ:LPTX) Sees Large Decline in Short InterestLeap Therapeutics, Inc. (NASDAQ:LPTX - Get Free Report) saw a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 1,050,000 shares, a decline of 7.1% from the July 15th total of 1,130,000 shares. Approximately 3.5% of the company's stock are short sold. Based on an average daily trading volume, of 145,200 shares, the short-interest ratio is presently 7.2 days.August 19, 2024 | marketbeat.comLeap Therapeutics, Inc.: Leap Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 15, 2024 | finanznachrichten.deQ3 2024 EPS Estimates for Leap Therapeutics, Inc. (NASDAQ:LPTX) Decreased by AnalystLeap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2024 earnings per share estimates for Leap Therapeutics in a research note issued to investors on Tuesday, August 13th. HC Wainwright analyst S. Ramakanth now forecasts that the compAugust 15, 2024 | marketbeat.comMaintained Buy Rating for Leap Therapeutics Amid Promising Clinical and Financial OutlookAugust 14, 2024 | markets.businessinsider.comLeap Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Trading Down 4.3%Leap Therapeutics (NASDAQ:LPTX) Shares Down 4.3%June 7, 2024 | marketbeat.comBuy Rating Affirmed for Leap Therapeutics Amid Promising Clinical Trials and Strategic ExpansionMay 14, 2024 | markets.businessinsider.comLeap Therapeutics (NASDAQ:LPTX) Given New $5.50 Price Target at HC WainwrightHC Wainwright decreased their price target on shares of Leap Therapeutics from $7.00 to $5.50 and set a "buy" rating for the company in a research note on Tuesday.May 14, 2024 | marketbeat.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q1 2024May 13, 2024 | investorplace.comLeap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2024 Financial ResultsMay 13, 2024 | finanznachrichten.deLeap Therapeutics Reports First Quarter 2024 Financial ResultsMay 13, 2024 | prnewswire.comLeap Therapeutics (NASDAQ:LPTX) Trading 0.6% Higher Leap Therapeutics (NASDAQ:LPTX) Trading Up 0.6%May 4, 2024 | marketbeat.comLeap Therapeutics To Sell $40 Mln Of Shares In Private Placement; Stock Up Over 14%April 11, 2024 | markets.businessinsider.comLeap Therapeutics Announces $40 Million Private PlacementApril 11, 2024 | prnewswire.com5 Best Biotech Penny Stocks to Invest InMarch 26, 2024 | insidermonkey.comQ1 2024 Earnings Estimate for Leap Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:LPTX)Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings estimates for Leap Therapeutics in a report released on Tuesday, March 19th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.58)March 21, 2024 | marketbeat.comLeap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy RatingMarch 19, 2024 | markets.businessinsider.comLeap Therapeutics (NASDAQ:LPTX) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Leap Therapeutics in a report on Tuesday.March 19, 2024 | marketbeat.comLeap Therapeutics (NASDAQ:LPTX) Price Target Cut to $9.00Robert W. Baird reduced their price target on shares of Leap Therapeutics from $11.00 to $9.00 and set an "outperform" rating on the stock in a research report on Tuesday.March 19, 2024 | marketbeat.comLPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023March 18, 2024 | investorplace.com Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address LPTX Media Mentions By Week LPTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LPTX News Sentiment▼0.000.60▲Average Medical News Sentiment LPTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LPTX Articles This Week▼01▲LPTX Articles Average Week Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ESSA Pharma News Forte Biosciences News Avalo Therapeutics News Applied Therapeutics News InterCure News Mural Oncology News Gain Therapeutics News PMV Pharmaceuticals News Ikena Oncology News Mersana Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LPTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
